Prognostic factors of a lower CD4/CD8 ratio in long term viral suppression HIV infected children.
No Thumbnail Available
Identifiers
Date
2019-08-05
Authors
Guillén, Sara
Prieto, Luis
Jiménez de Ory, Santiago
González-Tomé, María Isabel
Rojo, Pablo
Navarro, María Luisa
Mellado, María José
Escosa, Luis
Sainz, Talía
Francisco, Laura
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Combination antiretroviral therapy (cART) is associated with marked immune reconstitution. Although a long term viral suppression is achievable, not all children however, attain complete immunological recovery due to persistent immune activation. We use CD4/CD8 ratio like a marker of immune reconstitution. Perinatal HIV-infected children who underwent a first-line cART, achieved viral suppression in the first year and maintained it for more than 5 years, with no viral rebound were included. Logistic models were applied to estimate the prognostic factors, clinical characteristics at cART start, of a lower CD4/CD8 ratio at the last visit. 146 HIV-infected children were included: 77% Caucasian, 45% male and 28% CDC C. Median age at cART initiation was 2.3 years (IQR: 0.5-6.2). 42 (30%) children received mono-dual therapy previously to cART. Time of undetectable viral load was 9.5 years (IQR: 7.8, 12.5). 33% of the children not achieved CD4/CD8 ratio >1. Univariate analysis showed an association between CD4/CD8 1. Univariate analysis showed an association between CD4/CD8 CD4/CD8 >1 was not achieved in 33% of the children. Lower CD4 nadir and previous exposure to suboptimal therapy, before initiating cART, are factors showing independently association with a worse immune recovery (CD4/CD8 1 was not achieved in 33% of the children. Lower CD4 nadir and previous exposure to suboptimal therapy, before initiating cART, are factors showing independently association with a worse immune recovery (CD4/CD8
Description
MeSH Terms
Adolescent
Anti-Retroviral Agents
Antiretroviral Therapy, Highly Active
CD4-CD8 Ratio
Child
Child, Preschool
Female
HIV Infections
HIV-1
Humans
Immunity
Infant
Infant, Newborn
Male
Prognosis
Viral Load
Anti-Retroviral Agents
Antiretroviral Therapy, Highly Active
CD4-CD8 Ratio
Child
Child, Preschool
Female
HIV Infections
HIV-1
Humans
Immunity
Infant
Infant, Newborn
Male
Prognosis
Viral Load
DeCS Terms
CIE Terms
Keywords
Citation
Collections
SAS - Hospital Universitario Torrecárdenas
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
SAS - Hospital de Poniente
SAS - Hospital Universitario Puerta del Mar
SAS - Hospital Universitario Virgen de las Nieves
SAS - Hospital Universitario Virgen del Rocío
Load more Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
SAS - Hospital de Poniente
SAS - Hospital Universitario Puerta del Mar
SAS - Hospital Universitario Virgen de las Nieves
SAS - Hospital Universitario Virgen del Rocío